227Th is an interesting model for a short-lived bone 'surface-seeker' with αemission. The distribution after intraperitoneal injection of 227Th-citrate in the different organs is described. About 70 per cent of the injected Th was retained in the skeleton. The total dose burden depends to a high degree on distribution of decay products, especially 223Ra. Calculations were done for the skeletal dose burden in mice. They yielded 200 rads per 1 μCi of 227Th injected. The highest skeletal dose-rate (7 rads/day per 1 μCi/kg) was reached at the third day after injection. The possibility of bone sarcoma induction is discussed by comparison with dose relationships after incorporation of 228Th. A provisional mechanical technique is described for estimation - to a certain extent - of the activity at bone surface and volume separately.